Targeted Drug EGFR RTK Inhibitors for NSCLC market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Targeted Drug EGFR RTK Inhibitors for NSCLC market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Targeted Drug EGFR RTK Inhibitors for NSCLC market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Other
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India